Reference is made to the annual general meeting in Nordic Nanovector ASA on 28
June 2023 and the approval of a transaction whereby Nordic Nanovector will
acquire all outstanding shares in Thor Medical AS against issuance of new shares
in Nordic Nanovector. 

Scatec Innovation AS has, together with its subsidiaries Scatec Invest IV AS and
Scatec Invest II AS, previously agreed to sell its shares in Thor Medical
against receiving 61,901,306 shares in Nordic Nanovector subject to the approval
of the transaction by the annual general meeting. Pursuant to the agreement,
Scatec Innovation, on a consolidated basis, will upon subscription and delivery
of shares as resolved by the general meeting of Nordic Nanovector own a total of
61,901,306 shares in Nordic Nanovector, corresponding to approximately 26.51% of
the share capital and votes in the Company.

Scatec Innovation AS will own 57,151,062 shares directly, while Scatec Invest IV
AS will own 3,165,920 shares and Scatec Invest II AS will own 1,584,324 shares.
Scatec Invest IV AS and Scatec Invest II AS are both wholly owned subsidiaries
of Scatec Innovation AS. 

The ownership has been calculated on the assumption that a share capital
increase of NOK 146,841 related to board compensation and the share capital
increase of NOK 23,353,900.60 related to the acquisition of Thor Medical is
completed, resulting in a share capital in Nordic Nanovector of NOK
46,707,801.20 divided on 233,539,006 shares.

This disclosure is made pursuant to section 4-2 of the Norwegian Securities
Trading Act.